Objective To test whether azithromycin eradicates Ureaplasma from the respiratory tract in preterm infants.
Design Prospective, phase IIb randomised, double-blind, placebo-controlled trial.
Setting Seven level III–IV US, academic, neonatal intensive care units (NICUs).
Patients Infants 240–286 weeks’ gestation (stratified 240–266; 270–286 weeks) randomly assigned within 4 days following birth from July 2013 to August 2016.
Interventions Intravenous azithromycin 20 mg/kg or an equal volume of D5W (placebo) every 24 hours for 3 days.
Main outcome measures The primary efficacy outcome was Ureaplasma-free survival. Secondary outcomes were all-cause mortality, Ureaplasma clearance, physiological bronchopulmonary dysplasia (BPD) at 36 weeks’ postmenstrual age, comorbidities of prematurity and duration of respiratory support.
Results One hundred and twenty-one randomised participants (azithromycin: n=60; placebo: n=61) were included in the intent-to-treat analysis (mean gestational age 26.2±1.4 weeks). Forty-four of 121 participants (36%) were Ureaplasma positive (azithromycin: n=19; placebo: n=25). Ureaplasma-free survival was 55/60 (92% (95% CI 82% to 97%)) for azithromycin compared with 37/61 (61% (95% CI 48% to 73%)) for placebo. Mortality was similar comparing the two treatment groups (5/60 (8%) vs 6/61 (10%)). Azithromycin effectively eradicated Ureaplasma in all azithromycin-assigned colonised infants, but 21/25 (84%) Ureaplasma-colonised participants receiving placebo were culture positive at one or more follow-up timepoints. Most of the neonatal mortality and morbidity was concentrated in 21 infants with lower respiratory tract Ureaplasma colonisation. In a subgroup analysis, physiological BPD-free survival was 5/10 (50%) (95% CI 19% to 81%) among azithromycin-assigned infants with lower respiratory tract Ureaplasma colonisation versus 2/11 (18%) (95% CI 2% to 52%) in placebo-treated infants.
Conclusion A 3-day azithromycin regimen effectively eradicated respiratory tract Ureaplasma colonisation in this study.
Trial registration number NCT01778634.
- ureaplasma parvum
- ureaplasma urealyticum
- bronchopulmonary dysplasia
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
What is already known on this topic?
Respiratory tract colonisation with the genital mycoplasmas Ureaplasma parvum and U. urealyticum is an independent risk factor for bronchopulmonary dysplasia in extremely low gestational age infants.
The azalide antibiotic azithromycin has anti-inflammatory properties and exhibits high potency against Ureaplasma isolates in vitro.
Open-label pharmacokinetic/pharmacodynamics studies of single and multiple dose aizithromycin indicate that 20 mg/kg x3 days was most effective in eradicating respiratory tract Ureaplasma in preterms.
What this study adds?
In this randomised clinical trial that included 121 infants <29 weeks’ gestation, Ureaplasma-free survival was significantly higher in the azithromycin compared with the placebo group.
Ureaplasma was eradicated in all colonised infants assigned to azithromycin compared with 16% in colonised infants assigned to placebo.
Since neonatal mortality and morbidity was concentrated in infants with lower respiratory tract Ureasplasma colonisation, this population should be targeted in future phase III randomised controlled trial.
Ureaplasma respiratory tract colonisation is an independent risk factor for developing bronchopulmonary dysplasia (BPD) in preterm infants.1–4 Evidence from clinical studies,1 5 and experimental infection models,6–10 established lung Ureaplasma as proinflammatory and profibrotic, contributing to BPD alone or when combined with inflammatory stimuli such as hyperoxia or mechanical ventilation.8 Whether eradicating Ureasplasma from the developing lung will reduce the risk for BPD is unknown.
Since azithromycin exhibits high potency against clinical Ureaplasma isolates in vitro11 and immunomodulatory properties,12 it is an appropriate therapeutic candidate to eradicate Ureaplasma and reduce inflammation-mediated BPD in preterm infants.13 We conducted open-label, pilot studies characterising the population pharmacokinetics, safety and microbiological efficacy of intravenous 10 and 20 mg/kg single dose and 20 mg/kg x3d multidose azithromycin in 24–28 week gestation infants.14–16 In the open-label, uncontrolled 20 mg/kg multidose study, azithromycin eradicated Ureaplasma and appeared safe, with no deaths or serious adverse events attributed to the drug. We performed the current pilot (phase IIb) randomised clinical trial to test: (1) the feasibility of recruitment and Ureaplasma detection; (2) whether the 3-day azithromycin regimen was safe and was more effective than placebo to eradicate Ureaplasma in colonised infants; and (3) whether azithromycin would be beneficial or harmful in the subgroups of Ureaplasma-positive and Ureaplasma-negative infants. Respiratory outcomes were explored as potential endpoints for a later phase III trial.
Study design and oversight
Study design was a prospective, randomised, double-blind, placebo-controlled trial (clinicaltrials.gov NCT01778634). The U.S. Food and Drug Administration (IND78990) and the Institutional Review Board of each participating institution approved the study protocol. Written parental consent was obtained for all participants prior to randomisation. Recruitment was conducted in seven US academic, level III/IV neonatal intensive care units from July 2013 to August 2016. An independent data and safety monitoring committee reviewed unblinded data every 6 months to assess safety and study performance.
Eligible participants were extremely low gestation newborns (ELGAN) 240–286 weeks’ gestation (November 2013–January 2016), <72-hour postnatal age who received positive pressure ventilation for at least 1 hour. Since rapid diagnostic testing for Ureaplasma was not feasible, presence of Ureaplasma colonisation was not an inclusion criterion and was unknown at the time of recruitment. To focus enrollment on infants with the highest Ureaplasma prevalence, the protocol was revised to limit eligibility to the lower gestation stratum (240–266 weeks) for the last 6 months of enrollment (February–August 2016). Exclusion criteria were: non-viability or planned life support withdrawal; lethal congenital anomalies; >twin gestation; delivery for maternal indications; ECG corrected QT interval ≥450 ms; significant hepatic impairment; other systemic macrolide exposure; clinically suspected Ureaplasma CNS infection or culture-confirmed sepsis; or participation in other clinical trials.
Randomisation and intervention
Participants were stratified by gestational age (240–266 vs 270–286 weeks) and assigned in 1:1 ratio to azithromycin or placebo using separate randomisation schedules for each clinical site and stratum with twins assigned to the same treatment. The web-based randomisation system (Axio Research, Seattle, Washington, USA) used a permuted block design with varying block sizes of 2, 4 and 6. Baseline respiratory specimens were obtained; infants were randomised; and the first study drug dose administered within 24 hours of signed consent. Participants received azithromycin (American Pharmaceuticals Partners, Schaumburg, Illinois, USA) 20 mg/kg at a concentration of 2 mg/mL in 5% dextrose water or equal volume of 5% dextrose water (10 mL/kg) as a placebo intravenously via a peripheral or central line over 60 min every 24 hours for three doses. The primary care team at each site determined the fluid management of enrolled patients. Participants, care providers and study staff were blinded to treatment assignment.
Ureaplasma culture, antibiotic susceptibility testing and real-time PCR
Two tracheal aspirates (TAs) at least 2 hours apart and one nasopharyngeal sample from intubated infants, or two nasopharyngeal samples at least 2 hours apart from non-intubated infants were obtained for Ureaplasma culture and PCR before the first dose. Subsequent samples were obtained at 2 and 4–5 days after the last dose and 21 days postnatal age. Each specimen was frozen for later shipment to the University of Alabama at Birmingham Diagnostic Mycoplasma Laboratory for culture and azithromycin susceptibility testing. Species-specific real-time PCR15 was performed on all respiratory samples and each Ureaplasma isolate. Culture positivity was defined as a positive 10B broth culture from either TA or nasopharyngeal specimens confirmed by typical morphology. A culture was considered negative after no growth was detected for 7 days. Patients who were culture or PCR positive at any time point were classified as positive. Ureaplasma eradication was defined as three negative cultures post-treatment.
To accomplish an analysis according to the principle of intention to treat and avoid treating death as a good or neutral outcome, we defined our primary outcome as Ureaplasma-free survival (ie, survival to NICU discharge with three negative cultures post-treatment). Secondary outcomes were mortality, Ureaplasma clearance, physiological BPD at 36 weeks’ postmenstrual age (PMA) determined by a room air challenge (RAC), comorbidities of prematurity and duration of respiratory support. Participants were assessed at 36±1 weeks’ PMA and physiological BPD classified as present if they were receiving positive pressure respiratory support, nasal cannula flow ≥4 liters per minute (LPM or effective fractional inspired oxygen >0.317–19 or failed a RAC.20 To compare with BPD rates in other neonatal trials, participants were also classified according to the BPD severity21 and the modified Shennan classification22 that assigned infants on supplemental oxygen at 360 week as BPD present regardless of respiratory support and infants discharged home on room air <36 weeks’ PMA as BPD absent.
Sample size and statistical analysis
Using a two-sided α level of 0.05 and assuming an 80% overall survival rate in both groups, 20% twins and a 25% placebo clearance rate,23 the study would have power of 0.8 to detect an absolute 40% difference in the primary outcome of Ureaplasma-free survival with enrolment of 30 Ureaplasma-positive infants in each group. With an expected 45% respiratory prevalence23 and 5% drop-out rate, we planned to enrol 140 participants. The principal investigator (RV) ended recruitment without any information on the unblinded treatment comparisons when 121 neonates had been randomised because of interruption to funding.
For the efficacy analysis, we compared Ureaplasma eradication and other outcomes among all randomised participants according to the principle of intention to treat and in the subgroups of Ureaplasma-positive and Ureaplasma-negative participants to estimate the extent to which azithromycin had efficacy beyond clearance. To account for possible correlation between outcomes in twins, we used generalised estimating equations24 and multiple outputation.25 When observed counts were small, we used exact methods without accounting for twinning to calculate p values and CIs. Additional details of the statistical analysis plan are described in the online supplementary file 1.
In post hoc analyses, we explored the impact of lower respiratory tract Ureaplasma colonisation on the primary and major secondary outcomes.
All analyses were performed using SAS V.9.4.
Infants were recruited from seven sites over 37 months (July 2013–August 2016). A total of 982 patients were screened, of whom 434 (44%) were eligible (online supplementary figure 1S). Of 121 randomised, 60 were assigned to azithromycin and 61 were assigned to placebo; 119 (98%) received at least one dose of assigned treatment, one in each treatment group did not receive any doses of assigned treatment and treatment was discontinued in four azithromycin participants (one parent request and three clinical team request). All participants who received <3 doses were Ureaplasma negative. One placebo-assigned infant who was nasopharyngeal Ureaplasma positive received a single dose of azithromycin due to pharmacy error.
The baseline characteristics of randomised patients and stratified by Ureaplasma status are summarised in table 1. An imbalance in race distribution occurred with 40% non-white in the azithromycin versus 75% in the placebo group. Other baseline characteristics were similar comparing treatment arms for the entire study cohort and when stratified by Ureaplasma colonisation status.
Forty-four of 121 participants (36%) were Ureaplasma positive at one or more time points with 19 (32%) randomised to azithromycin and 25 (41%) to placebo (table 1 and online supplementary figure 2S). Ureaplasma prevalence was higher in the 240–266 weeks’ gestation stratum compared with 270–286 weeks (36/83 (43%) vs 8/38 (21%), p=0.02). Ureaplasma parvum was the most common species detected in both treatment arms (U. parvum, n=33 (75%); U. urealyticum n=7 (16%); both species, n=3 (7%); untyped n=1 (2%)). The Minimum inhibitory concentration (MIC)50 and MIC90 for Ureaplasma isolates were 2 µg/mL and 4 µg/mL, respectively. No tested isolate was resistant to azithromycin (MIC ≥16 µg/mL).
The Ureaplasma-free survival was higher in the azithromycin group (92% (95% CI 82% to 97%)) compared with the placebo group (61% (95% CI 48% to 73%)) (p<0.001) (table 2) and was sustained in analyses stratified by race (online supplementary table 1). For Ureaplasma-positive infants, Ureaplasma-free survival was higher in the azithromycin group (16/19 (84%), (95% CI 60% to 97%)) than in the placebo group (3/25 (12%), (95% CI 3% to 31%)) (p<0.001) (table 2). The proportion of infants who survived until discharge was similar in each treatment group (92% vs 90%, table 2). All follow-up cultures were negative in the azithromycin group, but 21/25 (84%) of colonised placebo subjects were culture positive at one or more follow-up time point (online supplementary figure S2). Seven azithromycin-assigned participants were PCR positive, but culture-negative post-treatment.
Two-thirds (12/19) of participants who met criteria for RAC, failed and were classified as physiological BPD. Three infants did not have a RAC completed so they could not be classified. There were no significant differences between treatment groups for the entire cohort or stratified by Ureaplasma colonisation status (table 2) or race (online supplementary table 1S) in overall survival, physiological BPD-free survival, frequency BPD by any classification or other secondary outcomes.
Post hoc analyses
Patients with lower respiratory tract Ureaplasma colonisation (n=21) were of lower gestation and birth weight than TA-negative intubated participants (n=52) and non-intubated infants (n=47) (table 3). In 5/52 (10%) TA-negative and 18/47 (38%) non-intubated neonates, one or more nasopharyngeal samples were Ureaplasma positive. Outcomes including Ureaplasma-free survival, overall survival, physiological BPD-free survival, durations of hospitalisation, mechanical ventilation and supplemental oxygen and postnatal steroid exposure were less favourable in patients with lower respiratory tract Ureaplasma colonisation than intubated infants without lower tract involvement or non-intubated patients (table 3). In patients with lower respiratory tract Ureaplasma colonisation, physiological BPD-free survival was 50% (5/10), (95% CI 19% to 81%) in azithromycin-treated versus 18% (2/11), (95% CI 2% to 52%) in placebo-treated infants (p=0.18) (table 4).
Common morbidities of prematurity occurring after randomisation and prior to hospital discharge were similar between treatment groups (table 5) and when stratified by race (online supplementary table 2S). Posthaemorrhagic hydrocephalus (PHH) was more common in the azithromycin-assigned compared with the placebo group (6 vs 0). Prior to dosing, IVH status was unknown in 4/6 of these infants; 1/6 had grade 2 IVH; and 1/6 received no azithromycin. Among those assigned to azithromycin, 11/56 (20%) had retinopathy of prematurity (ROP) >stage 2 compared with 4/56 (7%) assigned to placebo. ROP was more common in white infants in both treatment groups than non-white infants, which appears to explain most of this difference (online supplementary table 2S). There were no reported cases of infantile hypertrophic pyloric stenosis (IHPS) or QT-interval prolongation.
This pilot clinical trial demonstrates that: (1) respiratory tract Ureaplasma colonisation persists in untreated infants during the first three postnatal weeks; (2) 20 mg/kg x3d intravenous azithromycin effectively eradicates Ureaplasma from the respiratory tract in colonised ELGAN infants; and (3) ELGANs with lower respiratory tract Ureaplasma colonisation are a high risk group to target in future randomised trials. There is no evidence of an impact of azithromycin among Ureaplasma-negative infants.
The Ureasplasma eradication rate (100%) with the 3 days 20 mg/kg/day azithromycin regimen that was based on our open-label pharmacokinetics/pharmacodynamics studies14–16 was higher than but not inconsistent with eradication rates in previous trials of erythromycin (82%–86%)26 27 and clarithromycin (68.5%).28 However, some infants in the azithromycin group remained PCR-positive after treatment. This may represent residual DNA from dead organisms since no isolate was resistant. Effective clearance likely is dependent on factors such as pathogen virulence1 and variability in host immune response due to polymorphisms in host defence genes that may alter susceptibility to Ureaplasma and the inflammatory response.29
No current BPD definition is a strong predictor of long-term pulmonary outcomes.30 The recent increase in use of non-invasive respiratory support with room air has challenged classifications of BPD based on supplemental oxygen use. We selected three common BPD definitions as exploratory outcomes in the current trial. Completion of the study 2-year follow-up will allow us to compare the modified Shennan,22 BPD severity and physiological definitions’ predictive ability for later respiratory outcomes to better design a definitive phase III clinical trial.
Published reports on racial differences in preterm outcomes differ on which races experience more adverse perinatal outcomes31–33 or whether differences exist.34 In a recent prospective cohort of infants<29 weeks’ gestation, Wai et al 35 observed a lower incidence of BPD in black than white infants, but the frequency of respiratory morbidity during the first year of life was higher in black than white infants. In the Trial of Late Surfactant for Prevention of BPD (TOLSURF) clinical trial, black infants administered inhaled nitric oxide were less likely to develop BPD but experienced greater frequency of wheezing illness in the first 18–24 months of life.35 36 Since there was an imbalance by race in treatment groups in the current trial, we examined outcomes stratified by race. Our primary outcome finding of greater Ureaplasma-free survival with azithromycin was sustained in analyses stratified for race.
Azithromycin side effects are infrequent in adults and children.37 A recent study demonstrated an association of IHPS with oral azithromycin exposure in the first 14d of life in term38 and preterms 33–36 weeks’ gestation but not ≤32 weeks’ gestation.39 In addition, azithromycin is proarrhythmogenic with prior reports of occurrences of QT-interval prolongation and torsades de pointes in adults.40 Although there were no reported incidences of IHPS or QT interval prolongation in the infants in the current trial, adverse events must be monitored closely in any subsequent trial of azithromycin in the ELGAN population.
Since Ureaplasma spp. lack cell walls, they are susceptible to drying and heat contributing to false negatives, so that some affected infants may have been missed. We made efforts to avoid this misclassification by providing central laboratory culture medium, collection procedures optimised for organism recovery, multiple sampling sites at timepoints before and after study treatment and inclusion of PCR methods to better detect Ureaplasma. The race imbalance in randomisation did not influence the primary outcome, Ureaplasma-free survival, but influenced some secondary clinical outcomes. Future trials should consider stratifying on race. Brain imaging prior to randomisation was not required for this trial but, due to the observed differences in PHH, may be warranted in any future trial to better delineate the timing of IVH in relation to treatment.
Study implications summary
The results of this trial demonstrate the efficacy of azithromycin to eradicate Ureaplasma in ELGAN infants but do not support treatment of all ELGAN infants with azithromycin. Perinatal mortality and prolonged respiratory support are concentrated in ELGANs who have Ureaplasma in the lower respiratory tract. A phase III clinical trial in ELGAN infants with lower respiratory tract Ureaplasma would determine whether or not a 3-day course of azithromycin is of clinical benefit.
We would like to thank the parents of the participants of this trial and staff of participating NICUs and site study coordinators Elise Janofsky, Ashley Bathgate, Jennifer Shepard, Monika J. Thielen, Tara McNair, Amy Mackley, Kelly Gray and Steven Steele for assistance with patient recruitment. No compensation was received other than salary support for their contribution. We would like to thank the University of Alabama Diagnostic Mycoplasma Laboratory staff Donna Crabb and Melanie Fecanan for Ureaplasma culture and susceptibility testing and Amy Ratliffe for PCR. We would like to thank the University of Maryland School of Medicine Clinical and Translational Research Informatics Center for data management.
Correction notice This paper has been updated since it was published online. Author Namasivayam Ambalavanan’s first and last name were reversed and this has now been corrected.
Contributors RV, MLT, LSM and NLD had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: RV, MLT, LSM and NDE. Acquisition, analysis or data interpretation: all authors. Drafting of the manuscript: RV, MLT and LSM. Critical revision of the manuscript: all authors. Statistical Analysis: RV, MLT, LSM and NLD. Obtained funding: RV, MLT, LSM, SJD, PD, DAK, KBW, AN and NDE. Study supervision: RV, MLT, SJD, PD, DAK, AN, DJT, J-HW and KBW.
Funding This study was funded by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (R01 HD067126). NICHD had no role in the design and conduct of the study; data collection, management, analysis, and interpretation; preparation, review, or approval prior to submission of the manuscript.
Disclaimer The views expressed in this publication are those of the authors and not necessarily the views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access repository. Deidentified data analysis file, study protocol and statistical analysis plan will be accessible on the NICHD Data and Specimen Hub (URL pending).